Skip to content

Author

S. Di Cosimo

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Editorial Oct 2026

Rethinking tumour bed boost irradiation after pathological complete response in breast cancer.

Tumour bed boost irradiation has long represented a cornerstone of breast-conserving treatment, improving local control at the cost of increased fibrosis, poorer cosmetic outcomes, and reduced quality of life. However, the landscape of early breast cancer has changed profoundly. Modern systemic therapies and the widesp...

C. Giandini, M. G. Carnevale, R. Colciago et al. · 0 citations
Open access Oct 2026

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I-IIIA opera...

J. Pérez-García, J. Cortés, M. Ruíz-Borrego et al. · 0 citations
Review Open access Jul 2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.

S. Di Cosimo, V. Appierto, C. Reduzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.